The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
Salts of linogliride with reduced solubilities were prepared and evaluated as potential candidates for extended-release oral dosage forms. A once-daily dose of 300-800 mg was intended. Seven acids were selected: p-acetamidobenzoic, benzoic, p-hydroxybenzoic, 3-hydroxy-2-naphthoic, 1-napsylic, pamoic, and p-toluenesulfonic acids but only four salts were able to be prepared in suitable quantities for evaluation: linogliride pamoate, p-hydroxybenzoate, 3-hydroxy-2-naphthoate, and 1-napsylate. The pH-solubility profiles of the four new salts, free base, and fumarate salt were compared over the pH 1.43-8.3 range and the intrinsic dissolution rates of the four new salts and the free base were determined at pH 1.43, 4.4, and 7.5. The range of the pH-solubility profile and intrinsic dissolution rates of the p-hydroxybenzoate salt were less than the free base and fumarate and higher than the other three new salts. The pH-solubilities and intrinsic dissolution rates of the 1-napsylate salt were pH-independent. The solubilities and intrinsic dissolution rates of the pamoate and 3-hydroxy-2-naphthoate were higher at pH 1.4-3.4 than at higher pH. At pH 4.4 and higher, the solubilities were essentially the same, in the 1-2 mg/mL range. The intrinsic dissolution rates were also very low and not very different. Dissolution studies with capsules containing 800 mg doses of the pamoate, 1-napsylate, free base, and fumarate performed in a dissolution medium of pH beginning at 2.2 and ending at 6.8 demonstrated that the pamoate and 1-napsylate salt forms dissolved slower and could be useful as extended-release forms.
a Physical-Pharmacy Laboratory , McNeil Pharmaceutical , Spring House , PA , USA.
Frank A
FA
Chrzanowski
a Physical-Pharmacy Laboratory , McNeil Pharmaceutical , Spring House , PA , USA.|b College of Pharmacy , University of Cincinnati , Cincinnati , OH , USA.
Kaleem
K
Ahmad
D003692:Delayed-Action Preparations / Q000138:chemical synthesis* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D065546:Drug Liberation; D006863:Hydrogen-Ion Concentration; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000378:metabolism; D012492:Salts / Q000138:chemical synthesis* / Q000378:metabolism; D012995:Solubility
D003692:Delayed-Action Preparations; D011759:Pyrrolidines; D012492:Salts; C044425:linogliride
Extended release; intrinsic dissolution rate; pH-solubility profile; poorly soluble salts